Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team of international researchers, including scientists at the MRC Molecular Haematology Unit, report promising results from a phase I clinical trial of Enasidenib, a novel drug that may help patients suffering from Acute Myeloid Leukaemia.

None © Martin Phelps

Acute myeloid leukaemia (AML) is the most common aggressive leukaemia in adults and is incurable in most patients. Up to 15% of adult AML patients have a mutation in the IDH2 gene. The resulting abnormal IDH2 enzyme produces a chemical not normally found in blood cells called 2-hydroxyglutarate (2-HG). 2-HG stops the bone marrow from producing normal mature blood cells, including neutrophils and monocytes, cells that are essential for fighting life-threatening infections. Instead, immature leukaemia cells accumulate in the patient’s bone marrow and blood. AML patients need regular blood transfusions, and have a very poor immune system.

Most treatments for AML involve aggressive chemotherapy drugs that work by killing leukaemia cells, but these drugs have serious side-effects and are not suitable for the majority of AML patients. A new drug, Enasidenib, operates in a different way to conventional chemotherapy treatments. Instead of killing leukaemia cells, Enasidenib re-programmes them into neutrophils and monocytes that can function normally as part of a healthier immune system. An international team of researchers, including scientists at the MRC Molecular Hematology Unit at the MRC Wethearall Institute of Medicine, led by Prof Paresh Vyas and Dr Lynn Quek (Radcliffe Department of Medicine) recently published exciting results of their Phase 1 clinical trial of Enasidenib.

The researchers report that Enasidenib was effective in 40% of the 176 AML patients who participated in the study, with 19% achieving complete remission. Patients had improved immune systems and required fewer or no blood transfusions. In addition, the majority of participants showed few side effects to the drug. Crucially, most patients in this clinical trial had not responded to other AML treatments. Enasidenib represents an important addition to the currently limited range of effective treatments for this disease. 

The results of this clinical trial, together with supporting scientific data, have helped secure FDA approval for Enasidenib. The Oxford team is now leading the research programme to investigate why Enasidenib is not effective in all patients and if it can be more effective in combination with other AML therapies.

 

Find out more:

Amatangelo, Quek et al (2017) Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response, Blood, 130 (6) 732-741

Stein EM, DiNardo CD (2017) Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood, 130 (6) 722-731

Similar stories

Changes in blood cell production over the human lifetime may hold clues to patterns of disease

A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.

New Associate Professor appointments announced

Congratulations to Dr Bethan Psaila, Dr Benjamin Fairfax, Dr Hashem Koohy, Dr Andrew Blackford and Dr Oliver Bannard who have all been awarded the title of Associate Professor in recognition of their research achievements, contribution to teaching and contributions to the Medical Sciences Division.

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.